|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2011-3-17
|
|
pubmed:abstractText |
Cytarabine (ara-C) is an important drug in the treatment of acute myeloid leukemia (AML). High-dose cytarabine (2000 to 3000 mg per square meter of body-surface area) is toxic but results in higher rates of relapse-free survival than does the conventional dose of 100 to 400 mg per square meter. Intermediate dose levels have not been thoroughly evaluated.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Mar
|
|
pubmed:issn |
1533-4406
|
|
pubmed:author |
pubmed-author:BiemondBart JBJ,
pubmed-author:Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and...,
pubmed-author:FerrantAugustinA,
pubmed-author:GratwohlAloisA,
pubmed-author:GrauxCarlosC,
pubmed-author:GregorMichaelM,
pubmed-author:LöwenbergBobB,
pubmed-author:MaertensJohanJ,
pubmed-author:OssenkoppeleGert JGJ,
pubmed-author:PabstThomasT,
pubmed-author:SchaafsmaMartijn RMR,
pubmed-author:SchanzUrsU,
pubmed-author:SchoutenHarry CHC,
pubmed-author:SonneveldPieterP,
pubmed-author:TheobaldMatthiasM,
pubmed-author:VellengaEdoE,
pubmed-author:VerdonckLeo FLF,
pubmed-author:de GreefGeorgine EGE,
pubmed-author:van PuttenWimW
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
17
|
|
pubmed:volume |
364
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1027-36
|
|
pubmed:dateRevised |
2011-6-2
|
|
pubmed:meshHeading |
pubmed-meshheading:21410371-Adolescent,
pubmed-meshheading:21410371-Adult,
pubmed-meshheading:21410371-Antimetabolites, Antineoplastic,
pubmed-meshheading:21410371-Combined Modality Therapy,
pubmed-meshheading:21410371-Cytarabine,
pubmed-meshheading:21410371-Female,
pubmed-meshheading:21410371-Humans,
pubmed-meshheading:21410371-Intention to Treat Analysis,
pubmed-meshheading:21410371-Leukemia, Myeloid, Acute,
pubmed-meshheading:21410371-Male,
pubmed-meshheading:21410371-Middle Aged,
pubmed-meshheading:21410371-Prognosis,
pubmed-meshheading:21410371-Proportional Hazards Models,
pubmed-meshheading:21410371-Remission Induction,
pubmed-meshheading:21410371-Stem Cell Transplantation,
pubmed-meshheading:21410371-Survival Analysis,
pubmed-meshheading:21410371-Young Adult
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Cytarabine dose for acute myeloid leukemia.
|
|
pubmed:affiliation |
Erasmus University Medical Center, Department of Hematology (L413), P.O. Box 2040, 3000 CA Rotterdam, the Netherlands. b.lowenberg@erasmusmc.nl
|
|
pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
